A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Exclusion Criteria

• •Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational, or hormonal therapy for treatment of lymphoma within 28 days prior to treatment;
• •Exposure to bendamustine within the 180 days before study enrollment
• •Prior autologous or allogeneic stem cell transplantation (SCT);
• •Clinically significant abnormality on electrocardiogram (ECG) as determined by the treating physician or medical monitor;
• •History of other invasive malignancy within 5 years except for localized/in situ carcinomas;
• •Evidence of active infection, Confirmed current central nervous system involvement by leukemia or lymphoma;